Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN
Cancer Medicine · 2025
DOI: 10.1002/cam4.70953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yufeng Jiang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Key Laboratory of Pediatric Hematology …. Hauptthemen laut MEDLINE: Neuroblastoma, N-Myc Proto-Oncogene Protein, Purines, Cell Differentiation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Background
Neuroblastoma (NB), the common extracranial solid tumor in children, is associated with a poor prognosis, particularly in high‐risk patients. MYCN amplification stands as the most prominent molecular hallmark within this high‐risk subgroup. However, MYCN protein is considered “undruggable” due to its lack of a conventional enzymatic binding pocket and its predominant nuclear localization, which precludes targeting by standard small‐molecule inhibitors or antibody‐based therapeutics. Consequently, current therapeutic strategies have achieved limited efficacy against MYCN‐driven NB. Notably, MYCN not only orchestrates diverse metabolic reprogramming pathways in tumors but also exerts a pivotal influence on cellular differentiation. To overcome this therapeutic barrier, we seek to elucidate the contribution of purine metabolism to stemness maintenance in MYCN ‐amplified NBs and to discover novel small‐molecule inhibitors capable of inducing differentiation in high‐risk NBs.
Methods
Metabolomic profiling via mass spectrometry was employed to delineate differential metabolite signatures between MYCN ‐amplified and non‐amplified NB cells. Bioinformatics analysis of publicly available RNA sequencing datasets facilitated the systematic evaluation of purine metabolic enzyme expression. Cell differentiation, proliferation, colony formation, and cell migration assays were employed to assess the inhibitor's effects. Additionally, an in vivo xenograft model of NB was established to examine the therapeutic potential of lometrexol (LMX), a selective inhibitor of the purine biosynthesis enzyme phosphoribosylglycinamide formyltransferase (GART).
Results
Significant changes in nucleotide metabolism were identified in NB cell lines with high MYCN expression compared to those with low MYCN expression. The expression of purine metabolic enzyme genes was positively correlated with MYCN expression, prognosis, and differentiation status in NBs. Pharmacological inhibition of GART using LMX elicited a robust pro‐differentiation response, concomitant with a significant suppression of tumorigenic potential.
Conclusions
These findings establish purine metabolic enzyme inhibition as a viable therapeutic strategy to induce differentiation and attenuate tumor progression in high‐risk MYCN ‐amplified NBs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health, Shanghai, China.
- Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Key Laboratory of Pediatric Hematology & Oncology of China Ministry of Health, Shanghai,…
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of General Surgery, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Hongxiang Gao, Yanxin Li, Yijin Gao
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Jiang, Y., Xiao, H., Yang, Y., Chen, G., Zhang, Y., Wu, X., Zhang, Q., Huang, Q., Gao, H., Han, Y., Zhang, A., Jiang, D., Zheng, L., Li, Y., & Gao, Y. (2025). Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN. Cancer Medicine. https://doi.org/10.1002/cam4.70953
Vancouver
Jiang Y, Xiao H, Yang Y, Chen G, Zhang Y, Wu X, et al. Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN. Cancer Medicine. 2025. doi:10.1002/cam4.70953
BibTeX
@article{Jiang2025,
author = {Jiang, Yufeng and Xiao, Hui and Yang, Yi and Chen, Guoyu and Zhang, Yingwen and Wu, Xiaoyu and Zhang, Qi and Huang, Qingyi and Gao, Hongxiang and Han, Yali and Zhang, Anan and Jiang, Dapeng and Zheng, Liang and Li, Yanxin and Gao, Yijin},
title = {Inhibition of Purine Metabolism Promotes the Differentiation of Neuroblastoma Driven by MYCN},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70953}
}
EUVIMED